Table 1.
Demographic and Clinical Characteristics of the 3 Cohorts
| Characteristic | Chronic (n = 30) | Vaccine (n = 45) | Acute (n = 15) |
|---|---|---|---|
| Location | United States | United States | Nigeria |
| HIV subtype | Clade B | Clade B | Clade G and CRF02_AG |
| Age, y | 43.5 (22–54) | 26 (18–45) | 31 (18–40) |
| Race/ethnicity | |||
| African | 0 | 0 | 100 |
| African American | 80 | 4.4 | 0 |
| Hispanic | 0 | 24.4 | 0 |
| Mixed | 0 | 4.4 | 0 |
| White | 20 | 66.7 | 0 |
| Sex | |||
| Male | 66.7 | 46.7 | 46.7 |
| Female | 33.3 | 53.3 | 53.3 |
| Risk factor for HIV infection | NA | na | |
| Sex | 56.7 | … | … |
| Injection drug use | 43.3 | … | … |
| HIV load, RNA copies/mL | 2233 (<48–6 215 519) | NA | 114 715 (400–513 269) |
| CD4+ T-cell count, cells/µL | 604 (3–1778) | NA | na |
Data are % of subjects or median value (range), unless otherwise indicated. Subjects in the chronic cohort are HIV-infected individuals from Baltimore who are not receiving highly active antiretroviral therapy (n = 30) and include persons with broad HIV neutralization (n = 6), persons with restricted neutralization (n = 18), and persons with no neutralization (n = 6). Subjects in the vaccine cohort are individuals from the HIV Vaccine Trials Network 094 and 205 (n = 45). Subjects in the acute cohort are Nigerian HIV-infected individuals with a diagnosis of acute HIV infection (n = 15), 11 of whom were also followed for at least 1 year after infection.
Abbreviations: HIV, human immunodeficiency virus; NA, not applicable; na, not available.